Please select the option that best describes you:
Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?
For example, in patients with many swollen/tender joints, enthesitis, nail involvement do you expect particularly good response? Are there patients in whom you will choose to use bimekizumab as the first-line biologic?
Answer from: at Academic Institution
Bimekizumab might be especially beneficial for patients with a heavy burden of arthritis and psoriasis.
First line therapy for any new PsA/PsO drug is always difficult in the US but we try.
Sign in or Register to read more
Answer from: at Academic Institution
Bimekizumab has shown comparable efficacy in PsA patients who are TNFi naive and TNFi inadequate responders. Therefore, I would choose bimekizumab in bDMARD-IR patients. My second answer might surprise you - I would choose bimekizumab in a PsA patient with recurrent uveitis.